ADUS Addus HomeCare Corporation - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ADUS Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Care Facilities
Current Price
Live
$113.8
Analyst Target
$141.0
+23.9%
Upside
52W High
$124.44
52W Low
$88.96
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$2.1B
P/E
24.11
ROE
8.6%
Profit margin
6.4%
Debt/Equity
0.19
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
ADUS demonstrates strong financial health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and profitability trends. The company trades at a forward P/E of 16.58, below its sector average of 197.67, suggesting relative valuation attractiveness despite high sector-wide volatility. However, the absence of a dividend and bearish insider activity—marked by $9.53M in sales over six months—raise concerns about management confidence. While earnings growth remains robust at 12.7% YoY and recent quarters have consistently beaten estimates, the stock has underperformed over the past year with a -1.5% return. The intrinsic value of $122.96 exceeds the current price of $113.80, supporting a modest upside case.
Key Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational consistency
Consistent earnings beat rate (3 of last 4 quarters) with positive average surprise of 3.36%
Robust revenue growth of 25.00% YoY, outpacing sector average
Healthy balance sheet with low debt/equity (0.19) and strong current/quick ratios (1.66, 1.52)
Intrinsic value ($122.96) exceeds current price ($113.80), suggesting undervaluation on growth-adjusted basis
Key Risks
Bearish insider sentiment with $9.53M in sales over 6 months, including large sales by CEO and President
No dividend and zero payout ratio, limiting income appeal
Technical trend rated 0/100 (bearish), indicating short-term price weakness
Lack of analyst consensus (no target mean/recommendation), reducing visibility
Absence of Altman Z-Score raises concern about default risk, though Piotroski score mitigates this
AI Fair Value Estimate
Based on comprehensive analysis
$122.96
+8.0% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
68
Strong
78
80
75
85
20
AI Verdict
neutral
Key drivers: Strong Piotroski F-Score and earnings consistency, Attractive forward P/E relative to sector, Bearish insider activity and technical trend
Confidence
78%
Value
78/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 16.58 is below sector average of 197.67
- Intrinsic value ($122.96) exceeds current price ($113.80)
- Graham Number ($78.19) suggests conservative floor, but growth justifies premium
Watchpoints
- No PEG ratio available, limiting growth-adjusted valuation clarity
- High P/B (1.98) suggests potential overvaluation on book basis
Future
80/100
Ref Growth rates
Positives
- 25.00% YoY revenue growth and 12.70% earnings growth indicate strong momentum
- Recent Q/Q earnings growth of 13.30% shows acceleration
- Consistent earnings beats and positive surprises over 25 quarters
Watchpoints
- No forward guidance or PEG ratio to validate sustainability
- High growth may be difficult to maintain at current pace
Past
75/100
Ref Historical trends
Positives
- 25 consecutive quarters of earnings beats or positive surprises
- Improving EPS growth from +20.0% YoY to +4.7% Q/Q
- Stable margins with gross margin at 32.66% and operating margin at 9.50%
Watchpoints
- 5-year price change of -6.3% despite strong fundamentals
- Recent 1-year return of -1.5% suggests market skepticism
Health
85/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 7/9 indicates strong financial health
- Low debt/equity (0.19) and healthy liquidity ratios
- Positive ROE (8.58%) and ROA (6.87%)
Watchpoints
- No Altman Z-Score provided, limiting bankruptcy risk assessment
- Absence of EV/EBITDA and FCF data limits cash flow analysis
Dividend
20/100
Ref Yield, Payout
Positives
- 0% payout ratio implies no dividend risk
Watchpoints
- No dividend yield or payout history
- Zero dividend strength score (0/100) limits income appeal
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$113.8
Analyst Target
$141.0
Upside/Downside
+23.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADUS and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADUS
Addus HomeCare Corporation
Primary
|
-6.3% | +8.5% | -1.5% | -1.1% | +3.0% | +7.5% |
|
AORT
Artivion, Inc.
Peer
|
+72.4% | +236.1% | +40.5% | +37.0% | -8.2% | -0.8% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
AAPG
Ascentage Pharma Group Internat
Peer
|
+37.0% | +37.0% | +38.0% | -47.1% | -15.9% | -2.9% |
|
ATRC
AtriCure, Inc.
Peer
|
-33.0% | -7.6% | -3.2% | +24.0% | -3.6% | +0.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
24.11
Forward P/E
16.58
PEG Ratio
N/A
P/B Ratio
1.98
P/S Ratio
1.56
EV/Revenue
1.62
EV/EBITDA
13.86
Market Cap
$2.1B
Profitability
Profit margins and return metrics
Profit Margin
6.36%
Operating Margin
9.5%
Gross Margin
32.66%
ROE
8.58%
ROA
6.87%
Growth
Revenue and earnings growth rates
Revenue Growth
+25.0%
Earnings Growth
+12.7%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+13.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.19
Low debt
Current Ratio
1.66
Good
Quick Ratio
1.52
Excellent
Cash/Share
$5.59
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-23
$N/A
2025-11-03
$1.56
+1.7% surprise
2025-08-04
$1.49
+1.9% surprise
2025-05-05
$1.42
+6.5% surprise
Healthcare Sector Comparison
Comparing ADUS against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
P/E Ratio
24.11
This Stock
vs
197.69
Sector Avg
-87.8%
(Discount)
Return on Equity (ROE)
8.58%
This Stock
vs
-56.84%
Sector Avg
-115.1%
(Below Avg)
Profit Margin
6.36%
This Stock
vs
-20.8%
Sector Avg
-130.6%
(Weaker)
Debt to Equity
0.19
This Stock
vs
2.68
Sector Avg
-92.8%
(Less Debt)
Revenue Growth
25.0%
This Stock
vs
61.93%
Sector Avg
-59.6%
(Slower)
Current Ratio
1.66
This Stock
vs
3.47
Sector Avg
-52.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $2.1B | 24.11 | 8.6% | 6.4% | $113.8 | |
|
AORT
Artivion, Inc.
|
BEARISH | $2.04B | - | -2.5% | -2.2% | $43.02 | |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | |
|
AAPG
Ascentage Pharma Group Internat
|
BEARISH | $2.23B | - | -159.6% | -296.8% | $23.82 | |
|
ATRC
AtriCure, Inc.
|
NEUTRAL | $1.94B | - | -6.1% | -5.6% | $39.07 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | LOPEZ ESTEBAN | Director | Sale | 150 | $17,278 |
| 2025-12-05 | LOPEZ ESTEBAN | Director | Sale | 166 | $18,721 |
| 2025-11-19 | ANDERSON DARBY P | Officer | Sale | 20,000 | $2,180,000 |
| 2025-11-19 | ANDERSON DARBY P | Officer | Option Exercise | 20,000 | $454,000 |
| 2025-09-15 | DIXON HEATHER BRIANNE | President | Stock Award | 28,370 | - |
| 2025-09-02 | ALLISON R DIRK | Chief Executive Officer | Sale | 25,000 | $2,895,750 |
| 2025-09-02 | ALLISON R DIRK | Chief Executive Officer | Option Exercise | 25,000 | $492,750 |
| 2025-09-02 | BICKHAM W BRADLEY | President | Sale | 4,000 | $463,000 |
| 2025-08-25 | POFF BRIAN | Chief Financial Officer | Sale | 7,739 | $904,088 |
| 2025-08-20 | ALLISON R DIRK | Chief Executive Officer | Sale | 25,000 | $2,873,851 |
| 2025-08-20 | ALLISON R DIRK | Chief Executive Officer | Option Exercise | 25,000 | $492,750 |
| 2025-08-19 | HILL MILBOURNE VERONICA | Director | Sale | 1,571 | $180,555 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
13 analysts
BMO Capital
2025-11-13
Market Perform
RBC Capital
2025-11-07
Outperform
Outperform
TD Cowen
2025-11-05
Buy
Buy
Barclays
2025-11-04
Underweight
Underweight
Stephens & Co.
2025-09-03
Overweight
Overweight
UBS
2025-09-02
Buy
RBC Capital
2025-08-22
Outperform
Outperform
Barclays
2025-08-19
Underweight
Underweight
Past News Coverage
Recent headlines mentioning ADUS from our newsroom.
Newest → oldest
No matching news yet.